Nektar Therapeutics to Participate in Two Investor Conferences in September
4 september, 2025
Nektar Therapeutics to Participate in Two Investor Conferences in September
PR Newswire
SAN FRANCISCO, Sept. 3, 2025
SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 27 th Annual Global Investment Conference being held September 8-10, 2025 in New York City and the Stifel Virtual Immunology and Inflammation Forum being held September 15-16, 2025 .
- H.C. Wainwright 27 th Annual Global Investment Conference on Wednesday, September 10, 2025 – webcast to be available at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time – link here
- Stifel 2025 Virtual Immunology and Inflammation Forum on Monday, September 15, 2025 – webcast to be available at 2:30 p.m. Eastern Time / 11:30 a.m. Pacific Time – link here
The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events . Replays of the presentations will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California . For further information, visit www.nektar.com and follow Nektar on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
SOURCE Nektar Therapeutics
Nektar Therapeutics to Participate in Two Investor Conferences in September
4 september, 2025
Nektar Therapeutics to Participate in Two Investor Conferences in September
PR Newswire
SAN FRANCISCO, Sept. 3, 2025
SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 27 th Annual Global Investment Conference being held September 8-10, 2025 in New York City and the Stifel Virtual Immunology and Inflammation Forum being held September 15-16, 2025 .
- H.C. Wainwright 27 th Annual Global Investment Conference on Wednesday, September 10, 2025 – webcast to be available at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time – link here
- Stifel 2025 Virtual Immunology and Inflammation Forum on Monday, September 15, 2025 – webcast to be available at 2:30 p.m. Eastern Time / 11:30 a.m. Pacific Time – link here
The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events . Replays of the presentations will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California . For further information, visit www.nektar.com and follow Nektar on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
SOURCE Nektar Therapeutics
Ekholms sorti
Aktieanalys
Styrräntan
Ekholms sorti
Aktieanalys
Styrräntan
Marknadsöversikt
1 DAG %
Senast
1 mån
